These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21465870)

  • 1. Effects of medical therapies on retinopathy progression in type 2 diabetes.
    Egan A; Byrne M
    Ir Med J; 2011 Feb; 104(2):37. PubMed ID: 21465870
    [No Abstract]   [Full Text] [Related]  

  • 2. [Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study].
    Ai M; Yoshida M
    Nihon Rinsho; 2010 Nov; 68 Suppl 9():285-90. PubMed ID: 21661165
    [No Abstract]   [Full Text] [Related]  

  • 3. Fenofibrate and diabetic retinopathy.
    Liew G; Gillies M; Wang JJ
    Lancet; 2008 Mar; 371(9614):721; author reply 722. PubMed ID: 18313494
    [No Abstract]   [Full Text] [Related]  

  • 4. Retinopathy progression in type 2 diabetes.
    Baum SJ
    N Engl J Med; 2010 Nov; 363(22):2172; author reply 2173-4. PubMed ID: 21105808
    [No Abstract]   [Full Text] [Related]  

  • 5. Fenofibrate - a potential systemic treatment for diabetic retinopathy?
    Wong TY; Simó R; Mitchell P
    Am J Ophthalmol; 2012 Jul; 154(1):6-12. PubMed ID: 22709833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapies for diabetic retinopathy: the accord eye study.
    Frank RN
    Ophthalmology; 2014 Dec; 121(12):2295-6. PubMed ID: 25459462
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of diabetic retinopathy: could lipid-lowering be a worthwhile treatment modality?
    Dodson PM
    Eye (Lond); 2009 May; 23(5):997-1003. PubMed ID: 19169236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in risk of progression of diabetic retinopathy.
    Klein BE
    N Engl J Med; 2010 Jul; 363(3):287-8. PubMed ID: 20587586
    [No Abstract]   [Full Text] [Related]  

  • 9. Retinopathy progression in type 2 diabetes.
    Giral P; Rosenbaum D
    N Engl J Med; 2010 Nov; 363(22):2172; author reply 2173-4. PubMed ID: 21105807
    [No Abstract]   [Full Text] [Related]  

  • 10. Retinopathy progression in type 2 diabetes.
    Liew G; Wang JJ; Mitchell P
    N Engl J Med; 2010 Nov; 363(22):2171-2; author reply 2173-4. PubMed ID: 21105809
    [No Abstract]   [Full Text] [Related]  

  • 11. Fenofibrate for diabetic retinopathy.
    Simó R; Hernández C
    Lancet; 2007 Nov; 370(9600):1667-8. PubMed ID: 17988727
    [No Abstract]   [Full Text] [Related]  

  • 12. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.
    Chew EY; Davis MD; Danis RP; Lovato JF; Perdue LH; Greven C; Genuth S; Goff DC; Leiter LA; Ismail-Beigi F; Ambrosius WT;
    Ophthalmology; 2014 Dec; 121(12):2443-51. PubMed ID: 25172198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of medical therapies on retinopathy progression in type 2 diabetes.
    ; ; Chew EY; Ambrosius WT; Davis MD; Danis RP; Gangaputra S; Greven CM; Hubbard L; Esser BA; Lovato JF; Perdue LH; Goff DC; Cushman WC; Ginsberg HN; Elam MB; Genuth S; Gerstein HC; Schubart U; Fine LJ
    N Engl J Med; 2010 Jul; 363(3):233-44. PubMed ID: 20587587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fenofibrate and diabetic retinopathy.
    Cheung N; Wong TY
    Lancet; 2008 Mar; 371(9614):721-2; author reply 722. PubMed ID: 18313493
    [No Abstract]   [Full Text] [Related]  

  • 15. Diabetic retinopathy: treatment and prevention.
    Dodson PM
    Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S9-S11. PubMed ID: 17935059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mixed messages on systemic therapies for diabetic retinopathy.
    Lim LS; Liew G; Cheung N; Mitchell P; Wong TY
    Lancet; 2010 Oct; 376(9751):1461; author reply 1462. PubMed ID: 21036265
    [No Abstract]   [Full Text] [Related]  

  • 17. Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives.
    Simó R; Roy S; Behar-Cohen F; Keech A; Mitchell P; Wong TY
    Curr Med Chem; 2013; 20(26):3258-66. PubMed ID: 23745548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fenofibrate and diabetic retinopathy.
    Firth J
    Lancet; 2008 Mar; 371(9614):722; author reply 722. PubMed ID: 18313496
    [No Abstract]   [Full Text] [Related]  

  • 19. Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
    Burgess DC; Hunt D; Li L; Zannino D; Williamson E; Davis TM; Laakso M; Kesäniemi YA; Zhang J; Sy RW; Lehto S; Mann S; Keech AC
    Eur Heart J; 2010 Jan; 31(1):92-9. PubMed ID: 19797259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review.
    Czupryniak L; Joshi SR; Gogtay JA; Lopez M
    Expert Opin Pharmacother; 2016 Aug; 17(11):1463-73. PubMed ID: 27267786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.